A case for botulinum toxin-A in idiopathic bladder overactivity.
Botulinum toxin (BTX) has been shown to be an effective agent in suppressing detrusor overactivity due to neurogenic causes. Similar to results obtained with traditional agents to treat bladder overactivity (ie, antimuscarinic medications), the use of BTX has been extended to patients with idiopathic detrusor overactivity. This article briefly reviews the use of BTX to treat disorders of detrusor overactivity and, based on early clinical and laboratory results, establishes the case for its use as a therapeutic modality to treat idiopathic detrusor overactivity.
Smith
Christopher P
CP
Baylor College of Medicine, 6560 Fannin Street, #2100, Houston, TX 77030, USA.
Somogyi
George T
GT
Chancellor
Michael B
MB
Appell
Rodney A
RA
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D007267:Injections; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001743:Urinary Bladder / Q000187:drug effects / Q000503:physiopathology; D014549:Urinary Incontinence / Q000503:physiopathology / Q000628:therapy*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A